QUICK REFERENCE FOR HEALTHCARE PROVIDERS

MANAGEMENT OF NASOPHARYNGEAL CARCINOMA



Ministry of Health Malaysia



Malaysian Society of Otorhinolaryngologist - Head & Neck Surgeons (MSO-HNS)



Academy of Medicine Malaysia

KEY MESSAGES

- In Malaysia, nasopharyngeal carcinoma (NPC) is the fourth most common cancer. NPC is predominant among Chinese, followed by natives of Sabah and Sarawak (especially Bidayuh) and Malay.
- 2. Tobacco smoking is one of the important risk factors for NPC.
- 3. NPC is usually diagnosed late due to trivial presentation which leads to poor survival outcome.
- In patients presenting with cervical lymphadenopathy, full head and neck assessment and fine needle aspiration cytological examination of the nodes should be done.
- 5. NPC should be diagnosed by histopathological examination of the nasopharynx.
- 6. Staging of NPC is by using the tumour node metastasis (TNM) system American Joint Committee on Cancer or AJCC Cancer Staging Manual 2010 (7th Edition).
- 7. Primary treatment for NPC is radiotherapy. Intensity modulated radiotherapy is the preferred radiation technique.
- 8. Concurrent chemoradiotherapy should be offered in Stage II, III, IVA and IVB.
- 9. In recurrent NPC, nasopharyngectomy or re-irradiation may be offered.
- 10. Multimodality treatment including dental, supportive and palliative care should be considered in the management of NPC.

This Quick Reference provides key messages and a summary of the main recommendations in the Clinical Practice Guidelines (CPG) Management of Nasopharyngeal Carcinoma.

Details of the evidence supporting these recommendations can be found in the above CPG, available on the following websites:

Ministry of Health Malaysia Academy of Medicine Malaysia Malaysian Society of Otorhinolaryngologists Head & Neck Surgeons :www.moh.gov.my :www.acadmed.org.my :www.msohns.com

Also available as a mobile app for Android & IOS platform: MyMaHTAS

CLINICAL PRACTICE GUIDELINES SECRETARIAT

Health Technology Assessment Section Medical Development Division, Ministry of Health Malaysia 4th Floor, Block E1, Parcel E, 62590 Putrajaya Tel: 603-8883 1229 E-mail: <u>htamalaysia@moh.gov.my</u>

CLINICAL PRESENTATIONS AND REFERRAL

- Patients presenting with any of the following symptoms should be referred to Otorhinolaryngologists as soon as possible to rule out NPC :
 - o painless neck lump (unilateral/bilateral)
 - o blood-stained nasal discharge/saliva
 - o unilateral ear block or hearing loss
 - o headache
 - o facial numbness
 - o diplopia





Painless neck lump

NPC with ophthalmoplegia

RISK FACTORS OF NASOPHARYNGEAL CARCINOMA

- · Ethnicity (especially Chinese and natives of Sabah & Sarawak)
- Gender (male to female ratio is 3:1)
- · Family history of NPC
- · Lifestyle and environment
 - Tobacco smoking
 - Consumption of salted fish
 - Exposure to domestic wood cooking fires
 - Exposure to occupational solvents
 - Occupational exposure to wood dust

AJCC CANCER STAGING MANUAL 2010 (7TH EDITION)

Nasopharynx		
T1	Tumour confined to the nasopharynx, or tumor extends to oropharynx and/or nasal cavity without parapharyngeal extension*	
T2	Tumour with parapharyngeal extension*	
T3	Tumour involves bony structures of skull base and/or paranasal sinuses	
T4	Tumour with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space	
*Note: Parapharyngeal extension denotes posterolateral infiltration of tumour.		
N1	Unilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less, in greatest dimension*	
N2	Bilateral metastasis in cervical lymph node(s), ≤6 cm in greatest dimension, above the supraclavicular fossa*	
N3	Metastasis in a lymph node(s)* >6 cm and/or to supraclavicular fossa*	
N3a	>6 cm in dimension	
N3b	Extension to the supraclavicular fossa**	
*Note: Midline nodes are considered ipsilateral nodes.		
**Note: Supraclavicular zone or fossa is defined by three points:		

**Note: Supraclavicular zone or tossa is defined by three points:(1) the superior margin of the sternal end of the clavicle,

(2) the superior margin of the lateral end of the clavicle,
 (3) the point where the neck meets the shoulder.

All cases with lymph nodes (whole or part) in the fossa are considered N3b.

Distant Metastasis (M)

M0 No distant metastasis		M1 Distant meta	Distant metastasis	
Stage 0	NO		MO	
Stage I	T1	N0	MO	
Stage II	T1	N1	MO	
	T2	N0	MO	
	T2	N1	MO	
Stage III	T1	N2	MO	
	T2	N2	MO	
	Т3	N0	MO	
	Т3	N1	MO	
	Т3	N2	MO	
Stage IVA	T4	N0	MO	
	T4	N1	MO	
	T4	N2	MO	
Stage IVB	Any T	N3	MO	
Stage IVC	Any T	Any N	M1	

PROGNOSIS OF DIFFERENT NPC STAGES

Stage	Prognosis
T1-2 N0-1	Relatively good treatment outcome
T3-4 N0-1	Mainly local failure
T1-2 N2-3	Mainly regional and distant failure
T3-4 N2-3	Local, regional and distant failure

FOLLOW-UP SCHEDULE OF NPC WITHOUT RECURRENCE


Year after completion of treatment	Frequency of follow-up
First year	Every 1 to 2 months
Second year	Every 2 to 3 months
Third year	Every 3 to 5 months
Fourth to fifth year	Every 6 months
After fifth year	Every 6 to 12 months

*interval of follow-up may be adjusted based on clinical judgement

TOXICITIES OF RADIOTHERAPY ON HEAD AND NECK

ACUTE TOXICITIES			
 Lethargy Radiation dermatitis Mucositis Dysphagia 	 Taste changes Nausea and vomiting Haematological toxicities (neutropaenia) 		
LATE TOXICITIES			
Neurological Complications			
Temporal lobe injuries Cranial network	erve palsies • Lhermitte's syndrome		
Non-neurological Complications			
Tinnitus Hearing loss Otorrhea Trismus Dysphagia	Endocrinopathy - primary hypothyroidism - hypopituitarism Xerostomia		
Subcutaneous fibrosis	Second cancer within radiotherapy fields		

ALGORITHM A : MANAGEMENT OF NASOPHARYNGEAL CARCINOMA




- Head & neck and systemic examination (including nasopharyngoscopy):

Year	Intervals
First year	Every 1 to 2 months
Second year	Every 2 to 3 months
Third year	Every 3 to 5 months
Fourth to fifth year	Every 6 months
After fifth year	Every 6 to 12 months

- · Cross-sectional imaging in the initial 5 years
- · Speech/swallowing assessment as clinically indicated
- · Hearing evaluation & rehabilitation as clinically indicated
- Post-treatment dental management every 3 to 4 months by trained and experienced dental specialist
- · Weight assessment on follow-up
- Annual thyroid function test (TFT) screening

ALGORITHM B : MANAGEMENT OF PERSISTENT DISEASE OR RECURRENT NASOPHARYNGEAL CARCINOMA

- Restage to assess recurrent or persistent disease MRI or CT scan and PET/CT scan
- · Biopsy of recurrent lesion(s), as clinically indicated
- Treatment should be individualised based on patient performance status and extent
 of disease



Follow-up and Surveillance

- · Multidisciplinary team involvement (ENT specialist, oncologist, speech therapist, audiologist, etc)
- · Head & neck and systemic examination (including nasopharyngoscopy):

Year	Intervals
First year	Every 1 to 2 months
Second year	Every 2 to 3 months
Third year	Every 3 to 5 months
Fourth to fifth year	Every 6 months
After fifth year	Every 6 to 12 months

- · Cross-sectional imaging in the initial 5 years
- · Speech/swallowing assessment as clinically indicated
- · Hearing evaluation & rehabilitation as clinically indicated
- Post-treatment dental management every 3 to 4 months by trained and experienced dental specialist
- · Weight assessment on follow-up
- · Annual thyroid function test (TFT) screening

CHEMOTHERAPY DRUGS AND COMMON SIDE EFFECTS

CHEMOTHERAPY DRUGS	COMMON SIDE EFFECTS
Cisplatin	 Nausea and vomiting Myelosuppression Renal toxicity Electrolyte imbalance (hypomagnesaemia, hypocalcaemia, hypokalaemia) Auditory (tinnitus; with or without hearing loss)
Carboplatin	MyelosuppressionNausea and vomitingHypersensitivity reactionAlopecia
Fluorouracil	 Diarrhoea and stomatitis Myelosuppression Angina, myocardial infarction, arrhythmia, acute pulmonary oedema (special precaution) Alopecia
Docetaxel	 Myelosuppression Fluid retention Alopecia, cutaneous reaction, nails changes Stomatitis, diarrhoea, nausea and vomiting Hypersensitivity reaction